Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glucosamine sulfate and osteoarthritis

This article was originally published in The Tan Sheet

Executive Summary

Supplement ingredient may reduce the signs and symptoms of osteoarthritis of the knee, Jean-Yves Reginster, MD/PhD, et al., University of Liege, report at the American College of Rheumatology's annual scientific meeting in Boston Nov. 15. The double-blind, randomized, three-year trial compared 106 patients taking 1,500 mg glucosamine sulfate daily with 106 subjects taking placebo. Those taking the supplement showed no change in joint space narrowing, which was measured by radiograph, while the space between joints in those taking placebo narrowed an average of .08 mm to .1 mm per year. The researchers called on further studies to confirm the results; NCCAM recently announced it was funding a multicenter study on glucosamine and knee OA ("The Tan Sheet" Sept. 20, p. 10)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel